annual cash & cash equivalents:
$26.68M-$28.84M(-51.95%)Summary
- As of today (September 9, 2025), VKTX annual cash & cash equivalents is $26.68 million, with the most recent change of -$28.84 million (-51.95%) on December 31, 2024.
- During the last 3 years, VKTX annual cash & cash equivalents has risen by +$305.00 thousand (+1.16%).
- VKTX annual cash & cash equivalents is now -51.95% below its all-time high of $55.52 million, reached on December 31, 2023.
Performance
VKTX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$807.72M-$44.13M(-5.18%)Summary
- As of today (September 9, 2025), VKTX quarterly cash & cash equivalents is $807.72 million, with the most recent change of -$44.13 million (-5.18%) on June 30, 2025.
- Over the past year, VKTX quarterly cash & cash equivalents has dropped by -$134.54 million (-14.28%).
- VKTX quarterly cash & cash equivalents is now -16.12% below its all-time high of $962.98 million, reached on March 31, 2024.
Performance
VKTX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VKTX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -52.0% | -14.3% |
| 3 y3 years | +1.2% | +378.2% |
| 5 y5 years | +218.4% | +207.1% |
VKTX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -52.0% | +1.2% | -16.1% | +495.4% |
| 5 y | 5-year | -52.0% | +218.4% | -16.1% | +495.4% |
| alltime | all time | -52.0% | >+9999.0% | -16.1% | >+9999.0% |
VKTX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $807.72M(-5.2%) |
| Mar 2025 | - | $851.86M(-5.6%) |
| Dec 2024 | $26.68M(-51.9%) | $902.61M(-3.0%) |
| Sep 2024 | - | $930.44M(-1.3%) |
| Jun 2024 | - | $942.26M(-2.2%) |
| Mar 2024 | - | $962.98M(+166.0%) |
| Dec 2023 | $55.52M(+51.6%) | $362.08M(-3.8%) |
| Sep 2023 | - | $376.24M(-4.2%) |
| Jun 2023 | - | $392.92M(+189.6%) |
| Mar 2023 | - | $135.66M(-12.7%) |
| Dec 2022 | $36.63M(+38.9%) | $155.49M(+0.3%) |
| Sep 2022 | - | $155.02M(-8.2%) |
| Jun 2022 | - | $168.92M(-8.6%) |
| Mar 2022 | - | $184.90M(-8.5%) |
| Dec 2021 | $26.37M | $202.10M(-6.5%) |
| Sep 2021 | - | $216.13M(-5.3%) |
| Jun 2021 | - | $228.26M(-5.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $241.68M(-2.7%) |
| Dec 2020 | $29.12M(+247.6%) | $248.39M(-2.7%) |
| Sep 2020 | - | $255.30M(-2.9%) |
| Jun 2020 | - | $263.00M(-2.3%) |
| Mar 2020 | - | $269.16M(-10.7%) |
| Dec 2019 | $8.38M(-66.2%) | - |
| Dec 2018 | $24.78M(+175.7%) | $301.52M(+2192.8%) |
| Dec 2017 | $8.99M(+192.2%) | - |
| Dec 2016 | $3.08M(+300.2%) | $13.15M(-6.8%) |
| Dec 2015 | $768.50K(+1.7%) | $14.10M(-34.9%) |
| Jun 2015 | - | $21.66M(+6523.7%) |
| Mar 2015 | - | $327.00K(-63.3%) |
| Dec 2014 | $755.90K(+320.9%) | - |
| Jun 2014 | - | $891.50K(+1031.3%) |
| Mar 2014 | - | $78.80K |
| Dec 2013 | $179.60K(>+9900.0%) | - |
| Dec 2012 | $0.00 | - |
FAQ
- What is Viking Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Viking Therapeutics, Inc.?
- What is Viking Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Viking Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Viking Therapeutics, Inc.?
- What is Viking Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Viking Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of VKTX is $26.68M
What is the all time high annual cash & cash equivalents for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. all-time high annual cash & cash equivalents is $55.52M
What is Viking Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, VKTX annual cash & cash equivalents has changed by -$28.84M (-51.95%)
What is Viking Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of VKTX is $807.72M
What is the all time high quarterly cash & cash equivalents for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $962.98M
What is Viking Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, VKTX quarterly cash & cash equivalents has changed by -$134.54M (-14.28%)